← All organizations

Y-Mabs, Inc

For profitContributed to NMEWebsite ↗

Also known as: Y-mAbs Therapeutics | Y-mAbs Therapeutics, Inc | Y-mABs Therapeutics, Inc | Y-MABS THERAPEUTICS INC

Phase 1 Phase 2 Phase 3 Phase 4

Highest phase reached

Phase 3

First clinical trial

First marketed drug

First NDA

Last known activity

Sep 19, 2025

Timeline

2010s

Apr 1, 2014
Y-Mabs, Inc— Founded

2020s

Nov 25, 2020
naxitamab— Marketing Organization
Nov 25, 2020
naxitamab— NDA Organization
Nov 25, 2020
naxitamab— NDA Secondary Org

Drugs by trial phase (18 distinct, 19 trials)

Phase 3 (3 own, 0 via acquisition)

Phase 2 (11 own, 0 via acquisition)

Phase 1 (4 own, 0 via acquisition)

Indications

Studied for

Marketed drugs (1)

naxitamab

Recent trials (20)

NCT05064306CollaboratorN/A—
NCT07011654CollaboratorPhase 1/Phase 2Sep 19, 2025
NCT07027748CollaboratorPhase 1Jun 27, 2025
NCT05994157Lead sponsorPhase 1Feb 29, 2024
NCT05130255Lead sponsorPhase 1May 31, 2022
NCT05077423Lead sponsorPhase 1Dec 31, 2021
NCT05063357Lead sponsorPhase 1Dec 31, 2021
NCT04909515Lead sponsorPhase 2Oct 31, 2021
NCT04743661CollaboratorPhase 2Oct 1, 2021
NCT04750239Lead sponsorPhase 1/Phase 2Aug 17, 2021
NCT04560166Lead sponsorPhase 3Dec 31, 2020
NCT04315246Lead sponsorPhase 1/Phase 2Oct 31, 2020
NCT04167618Lead sponsorPhase 1/Phase 2Apr 30, 2020
NCT04022213CollaboratorPhase 2Jul 15, 2019
NCT03275402Lead sponsorPhase 2/Phase 3Sep 30, 2018

Details

Founded: New York, NY, US Apr 1, 2014
First NDA: Nov 25, 2020
Last known activity: Sep 19, 2025

Designations held

Orphan drug
Priority review
Breakthrough therapy
Accelerated approval